Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Nvidia (NVDA) CEO Jensen Huang took to the stage Tuesday afternoon to deliver his keynote speech at the chip giant's 2025 GTC event (GPU Technology Conference), where he previewed the company's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Attributing a work to the artist generally requires authentication by the Van Gogh Museum, but lawsuits and an influx of requests have made it reassess that role. By Nina Siegal A new cultural ...

PC hardware is nice, but it’s not much use without innovative software. I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo ...

President Donald Trump’s flurry of executive orders since returning to the White House is shaking up the art world. Restrictions on Diversity, Equity, and Inclusion initiatives are already ...